# AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

> **NCT02218047** · PHASE3 · COMPLETED · sponsor: **AOP Orphan Pharmaceuticals AG** · enrollment: 170 (actual)

## Conditions studied

- Polycythemia Vera

## Interventions

- **DRUG:** Pegylated-Proline-interferon alpha-2b
- **DRUG:** Best available therapy (BAT)

## Key facts

- **NCT ID:** NCT02218047
- **Lead sponsor:** AOP Orphan Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2021-04-29
- **Final completion:** 2021-04-29
- **Target enrollment:** 170 (ACTUAL)
- **Last updated:** 2021-06-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02218047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02218047, "AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02218047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*